Weekly alirocumab for high cholesterol study
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests if a weekly injection of alirocumab (Praluent) is safe and effective for people with high cholesterol. It aims to help lower LDL cholesterol that has not responded enough to current treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high LDL ('bad') cholesterol that isn't controlled enough yet.
- You are not planning to start or change any cholesterol-lowering medicines soon.
- You have never taken a PCSK9 inhibitor (a newer type of cholesterol shot) before.
- You are 18 or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a cholesterol-lowering injection (alirocumab) helps people who are on regular dialysis. It aims to improve cholesterol control in a carefully selected group and tracks safety during treatment.
This study follows people who are already taking PCSK9 inhibitor shots to see how well patients stay on treatment and how effective it is. Your participation would mainly be about consenting to provide basic information and possibly follow-up details.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This trial tests a new medicine, SHR-1918, for people whose bad cholesterol (LDL-C) stays high even when they take statins and another type of cholesterol-lowering drug called a PCSK9 inhibitor. It aims to see if this additional treatment can lower their cholesterol more effectively.
This study tracks how well patients stick to and benefit from alirocumab 300mg, a cholesterol-lowering injection. It looks at real-world use in Italy.
This Phase 1 study tests how safe a cholesterol-lowering antibody (alirocumab) is in people who drink heavily but are not seeking alcohol treatment. It also looks at early drug effects in the body to see how it might change cholesterol-related signals.
Hear when a new Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.